Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
about
Immunotherapy for stage I-III non-small cell lung cancer treated with surgery or radiotherapy with curative intentMetastatic Breast Tumour Regression Following Treatment by a Gene-Modified Vaccinia Virus Expressing MUC1 and IL-2Immunotherapy for lung cancer: advances and prospectsTherapeutic vaccines in non-small cell lung cancerLung cancer vaccinesModified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccinesBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerp53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responsesCancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.Immune therapy for breast cancer in 2010-hype or hope?A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.Altered intracellular region of MUC1 and disrupted correlation of polarity-related molecules in breast cancer subtypes.Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer VaccinesMVA as a vector for vaccines against HIV-1.Gene-based vaccines and immunotherapeutics.B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals.MUC1 as a target antigen for cancer immunotherapy.Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic realityA fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector.5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple MyelomaTargeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerClinical development of MVA-based therapeutic cancer vaccines.Vaccine therapy for renal cancer.Strategies used for MUC1 immunotherapy: human clinical studies.Lister strain of vaccinia virus armed with endostatin-angiostatin fusion gene as a novel therapeutic agent for human pancreatic cancerRadiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.Non-small-cell lung carcinoma vaccines in clinical trials.Active immunotherapy for non-small-cell lung cancer: moving toward a reality.The use of plants for the production of therapeutic human peptides.MUC1 immunotherapy is here to stay.Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer.Role of immunotherapy in castration-resistant prostate cancer (CRPC).A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?
P2860
Q24194081-7ECCB6D6-5ABA-46DB-9072-B225574F05EFQ24792515-FBA932AA-A8AD-40C9-A946-9B69389E0185Q26750617-157A879A-811B-433A-8C48-0F61CFCE64C1Q26864896-7D94BD6E-7D56-4916-BDD9-B1A246CA550EQ27014375-38D35368-0C46-4C7D-A0C8-12F5357B6835Q33653229-81A73B0B-8532-4826-8A4D-752CB578D1C4Q33862861-74A03CDC-B8A2-491F-B682-EE37FD5F39E6Q34135426-C5690E25-E46A-444B-8B5F-95E9375691D2Q34494018-0772A2F9-39AE-41C3-BED4-DB1998BC136CQ34541467-CAB2CF1D-709A-47EC-AF8C-74461FCCB4E8Q34733314-44DDDEC2-C6B2-4D1B-A612-06B06D174AE8Q35223889-928583F8-A910-4A70-9D81-3FA19B25ED54Q35677112-F8FD86EB-DFC0-4C57-A79B-FEB41B72B48DQ35774908-7D1555BE-E9B2-460A-BA42-84E30F124FA5Q35851793-E57D4AA5-49EB-4F4E-A36D-20FF94F80425Q35873176-E956E717-F29C-45A0-9049-F3DBB15B719FQ36103012-83817395-5BEA-404A-A112-B9A4521E27CDQ36238699-89340792-B149-493F-B0A3-C6E2A1706DCAQ36326572-3D189B06-03FB-4CF2-8121-3BFF116211FAQ36824066-54C0F9C9-69A1-4F65-9396-E5B946D1C9E3Q36922276-8D343C4D-195D-458F-A94A-62AFAF3AC841Q37074226-40720761-63C6-4405-966F-67B463BED1AEQ37210703-51A51BEC-CD4E-4AE1-A37B-F42CD1209924Q37246286-4D5470E0-17A2-4938-ACDD-78981EF70296Q37259579-D361CD2D-E78A-4E40-A4C1-F145C598CC4DQ37259586-E323B203-F606-40D6-8F4C-FC9261948976Q37259597-96263D31-931D-4363-892C-4B4D7D0B3F69Q37389574-703D37DA-5F97-42E6-B239-601924668CEFQ37589407-B0395D38-1FEE-4A40-BA2D-2EBAD23C9C7FQ37678414-958F2752-14B3-446F-BE33-D0AA343CFE49Q37737313-4BF10973-BEDB-4C8B-8B2D-86FC287D6243Q37892598-49053D35-7FE4-49CA-98B8-655F8E6DB439Q37945644-5264CD01-03B4-4FEC-A705-0F90808EC0D9Q37973256-26A7C92C-2FF0-4A76-9838-383264C40880Q38045428-101C2D47-7CDB-4F4B-A7DD-CE116E283FC6Q38072813-DAE6E1C2-C887-488C-9DFA-2D062998ACECQ38089936-E3C7EF42-031A-448D-B166-6E517EBF8098Q38104730-0DB5DC76-030D-4623-AD55-84D7BFCE4041Q38172644-FB17E7AD-2F13-44A3-9FF8-9E0B3E3E05D4Q38242271-D4B18A21-79A4-4438-B0DD-82F8634417EF
P2860
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Phase I immunotherapy with a m ...... MUC1-positive advanced cancer.
@en
Phase I immunotherapy with a modified vaccinia virus
@nl
type
label
Phase I immunotherapy with a m ...... MUC1-positive advanced cancer.
@en
Phase I immunotherapy with a modified vaccinia virus
@nl
prefLabel
Phase I immunotherapy with a m ...... MUC1-positive advanced cancer.
@en
Phase I immunotherapy with a modified vaccinia virus
@nl
P2093
P356
P1476
Phase I immunotherapy with a m ...... MUC1-positive advanced cancer.
@en
P2093
Bruce Acres
Christoph Rochlitz
Marc Salzberg
Martine Baudin
Miklos Pless
Nadine Bizouarne
Patrick Squiban
Richard Herrmann
Robert Figlin
Yongxiang Zhao
P304
P356
10.1002/JGM.397
P50
P577
2003-08-01T00:00:00Z